Vincent Kempinski
Adult Health · Marshall, MINPI 1831118397
Payments from drug & device makers
Across 95 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$405
- Biohaven Pharmaceutical Holding Company Ltd.$121
- Otsuka America Pharmaceutical, Inc.$120
- Xeris Pharmaceuticals, Inc.$116
- Johnson & Johnson$112
- Lilly USA, LLC$78
- plus $695 from 23 others
What the payments were for
- Food & beverage$1,647100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $405 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $121 |
| Otsuka America Pharmaceutical, Inc. | 7 | $120 |
| Xeris Pharmaceuticals, Inc. | 6 | $116 |
| Johnson & Johnson | 7 | $112 |
| Lilly USA, LLC | 5 | $78 |
| Biohaven Pharmaceuticals, Inc. | 2 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $68 |
| AbbVie | 4 | $57 |
| Abbott | 3 | $56 |
| Pfizer | 3 | $49 |
| Neurocrine Biosciences, Inc. | 2 | $49 |
| Amarin Pharma, Inc. | 3 | $39 |
| Amgen | 2 | $35 |
| Boston Scientific | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $23 |
| Indivior Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Insulet Corporation | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Orexo US, Inc. | 1 | $12 |
| AstraZeneca | 1 | $12 |
How this compares
$1,647 in reported general payments places this provider in the 75th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $130,875 |
| Invega SustennaPaliperidone Palmitate | 30 | $71,839 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 84 | $8,216 |
| Clozapine | 94 | $6,842 |
| Quetiapine Fumarate | 242 | $5,240 |
| Paliperidone ErPaliperidone | 36 | $5,029 |
| Lurasidone Hcl | 76 | $3,341 |
| Olanzapine | 176 | $2,837 |
| Buspirone Hcl | 130 | $2,604 |
| Aripiprazole | 81 | $2,146 |
| Trazodone Hcl | 157 | $2,067 |
| Atomoxetine Hcl | 14 | $1,682 |
| Desmopressin Acetate | 14 | $1,671 |
| Lorazepam | 84 | $1,421 |
| Divalproex Sodium ErDivalproex Sodium | 38 | $1,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $49 | $130,87517 claims |
| Johnson & JohnsonInvega Sustenna | $112 | $71,83930 claims |
| Lilly USA, LLCOlanzapine | $78 | $2,837176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 527 adult health providers in Michigan.
Other adult health in Marshall
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
- Mary KaiserKalamazoo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.